Initiate PR is far more than a communications agency. We are steeped in healthcare policy going back more than 30 years.
So we are pleased to see these experts joining the fight for medical innovation without the misleading political rhetoric from both parties, that has clouded the issue.
Medscape By Roxanne Nelson, BSN, RN http://www.medscape.com/viewarticle/878871 April 21, 2017
Some of the strategies used by health insurance companies to control drug costs are having a negative impact on patients with cancer, says the American Society of Clinical Oncology (ASCO) in a new statement.
CNN: How to cut the price of prescription drugs: http://www.cnn.com/…/prescription-drug-pricing-competition…/ by Scott W. Atlas, MD, at Stanford University’s Hoover Institution
“we already know from history that price caps don’t provide the desired products at lower prices; instead, caps always restrict the availability of the product, whether that product be gasoline for cars, rent for apartments or anything else.
Drugs are no different. Iain Cockburn, a professor of management at Boston University, used data on launches of 642 new drugs in 76 countries to show that price regulation strongly delays drug launches. And Thomas Abbott with John Vernon, health care economists at the University of Connecticut, showed that pharmaceutical price controls significantly diminish the incentives to undertake early stage research and development investment. In that study, cutting prices by 40% to 50% in the United States will lead to 30-60% fewer early stage research and development projects.
And Rexford Santerre, a professor of health care management at the University of Connecticut, calculated that drug price controls would have led to 198 fewer new drugs being brought to the US market from 1981 to 2000, and at a cost of about $100 billion more than the estimated consumer savings from those drug price controls.”